GPR30在宫颈癌细胞生长中的作用及其机制研究

发布时间：2018-05-06 08:48

本文选题：宫颈癌 + G蛋白耦联受体　；参考：《现代妇产科进展》2015年01期

【摘要】：目的:体外研究雌激素膜受体GPR30对宫颈癌细胞生长的影响及其作用机制。方法:选择宫颈腺癌HeLa和宫颈鳞癌SiHa细胞株,分别用GPR30特异性激动剂G1和拮抗剂G15处理宫颈癌细胞株。RT-PCR、Western blot法检测处理前后宫颈癌HeLa与SiHa细胞中GPR30、TLR3 mRNA及其蛋白表达变化;MTT法检测G1、G15及Poly I:C处理对宫颈癌细胞生长的影响。结果:(1)HeLa细胞中GPR30表达量高于SiHa细胞。G1处理后HeLa、SiHa细胞中GPR30 mRNA及其蛋白表达水平增高,与对照组比较,差异有统计学意义(P0.05;P0.05);G15处理后,HeLa、SiHa细胞中GPR30 mRNA及其蛋白表达水平降低,与对照组比较,差异有统计学意义(P0.05;P0.05)。(2)HeLa、SiHa细胞中TLR3 mRNA表达量分别为(0.5327±0.05373)、(0.3526±0.05774),蛋白表达量分别为(0.3572±0.097039)、(0.5002±0.09718)。G1能降低He La、Si Ha细胞中TLR3mRNA及其蛋白表达水平,G1 10-6mol/L处理组与对照组比较差异有统计学意义(P均0.05)。G15能增高HeLa、SiHa细胞中TLR3 mRNA及其蛋白表达水平,G15 10-5mol/L处理组与对照组比较,差异有统计学意义(P均0.05),与Poly I:C处理组比较差异无统计学意义(P0.05)。(3)10-6mmol/L、10-5mmol/L G1分别处理后,宫颈癌HeLa、SiHa细胞生长增殖率分别为(16.68±5.86)%、(26.67±3.25)%及(14.99±6.43)%、(22.72±1.77)%,与空白对照组相比,差异有统计学意义(P均0.05)。10-6mmol/L、10-5mmol/L G15分别处理后,宫颈癌HeLa、SiHa细胞的生长抑制率分别为(21.09±2.32)%、(22.99±3.15)%及(15.86±6.49)%、(19.18±2.61)%,与空白对照组相比,差异有统计学意义(P均0.05)。结论:宫颈癌细胞中存在雌激素膜受体GPR30表达,宫颈腺癌细胞中GPR30表达量高于宫颈鳞癌细胞,体外调节GPR30表达可影响宫颈癌细胞生长。抑制GPR30表达可通过上调TLR3表达而抑制宫颈癌细胞生长,GPR30可能成为宫颈癌治疗的新靶点。
[Abstract]:Aim: to study the effect of estrogen membrane receptor (GPR30) on the growth of cervical cancer cells in vitro. Methods: cervical adenocarcinoma HeLa and cervical squamous cell carcinoma SiHa cell lines were selected. GPR30 specific agonist G1 and antagonist G15 were used to detect the expression of GPR30TLR3 mRNA and its protein in HeLa and SiHa cells before and after treatment. Results the expression of GPR30 in HeLa cells was higher than that in SiHa cells. G1 treated HeLa-SiHa cells increased the expression of GPR30 mRNA and its protein. Compared with the control group, the expression level of GPR30 mRNA and its protein in HeLaSiHa cells decreased significantly after treatment with P0.05 and P0.05P0.05. Compared with the control group, There was significant difference in the expression of TLR3 mRNA in he Lasiha cells, which were 0.5327 卤0.05373, 0.3526 卤0.05774, and 0.3572 卤0.0970399.500 2 卤0.09718).G1 in he LasiHa cells, respectively. There was significant difference between the G1 10-6mol/L treatment group and the control group in TLR3mRNA and protein expression level of he LaSiHa cells. There was significant difference between the G 1 10-6mol/L treatment group and the control group. The expression level of TLR3 mRNA and its protein in He-La-SiHa cells was increased. Compared with the control group, the G15 10-5mol/L treatment group could increase the expression of TLR3 mRNA and its protein. The difference was statistically significant (P < 0.05). Compared with Poly I / C treatment group, there was no significant difference between the two groups. After 10 ~ (-6) mmol / L ~ (-1) 10 ~ (-6) mmol 路L ~ (-1) L ~ (-1) treatment, the growth and proliferation rates of cervical cancer HeLa Siha cells were 26.68 卤5.86% and 14.99 卤6.43 ~ 22.72 卤1.77, respectively, compared with the blank control group. After treated with 10-5 mmol / L G15, the growth inhibition rates of cervical cancer HeLa-SiHa cells were 21.09 卤2.32, 22.99 卤3.15% and 15.86 卤6.49 卤19.18 卤2.61, respectively. The difference was statistically significant compared with the control group (P 0.05). Conclusion: there is estrogen membrane receptor (GPR30) expression in cervical carcinoma cells. The expression of GPR30 in cervical adenocarcinoma cells is higher than that in cervical squamous cell carcinoma cells. Regulation of GPR30 expression in vitro can affect the growth of cervical cancer cells. Inhibition of GPR30 expression can inhibit the growth of cervical cancer cells by up-regulating TLR3 expression. GPR30 may become a new target of cervical cancer therapy.
【作者单位】：天津医科大学一中心临床学院;天津市卫生部危重病急救医学重点实验室;
【分类号】：R737.33

【相似文献】